Q4 2019 EPS Estimates for NeoGenomics, Inc. Raised by Analyst (NASDAQ:NEO)
NeoGenomics, Inc. (NASDAQ:NEO) – Analysts at Svb Leerink boosted their Q4 2019 earnings per share (EPS) estimates for shares of NeoGenomics in a research note issued to investors on Tuesday, October 29th. Svb Leerink analyst P. Souda now expects that the medical research company will post earnings per share of $0.07 for the quarter, up from their prior forecast of $0.05.
NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, October 29th. The medical research company reported $0.07 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.01. The business had revenue of $104.70 million for the quarter, compared to analysts’ expectations of $99.38 million. NeoGenomics had a return on equity of 4.60% and a net margin of 0.55%. The company’s quarterly revenue was up 51.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.05 EPS.
Several other analysts have also recently commented on NEO. Benchmark set a $27.00 target price on NeoGenomics and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Needham & Company LLC raised their target price on NeoGenomics from $27.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday. Raymond James raised their target price on NeoGenomics from $23.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 31st. Zacks Investment Research cut NeoGenomics from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, Leerink Swann set a $30.00 target price on NeoGenomics and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $24.86.
Shares of NASDAQ NEO traded down $0.25 during mid-day trading on Friday, reaching $22.68. The company had a trading volume of 664,800 shares, compared to its average volume of 1,004,603. The stock has a market cap of $2.43 billion, a PE ratio of 174.38 and a beta of 0.92. The company has a 50-day moving average price of $20.50 and a two-hundred day moving average price of $22.43. The company has a current ratio of 4.24, a quick ratio of 4.52 and a debt-to-equity ratio of 0.24. NeoGenomics has a 1-year low of $11.05 and a 1-year high of $26.89.
In other NeoGenomics news, Director Steven C. Jones sold 40,737 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $25.02, for a total value of $1,019,239.74. Following the completion of the sale, the director now owns 245,234 shares of the company’s stock, valued at $6,135,754.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Steven C. Jones sold 181,339 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $24.92, for a total value of $4,518,967.88. Following the completion of the sale, the director now directly owns 245,234 shares of the company’s stock, valued at approximately $6,111,231.28. The disclosure for this sale can be found here. In the last ninety days, insiders sold 241,370 shares of company stock valued at $6,017,680. 8.80% of the stock is currently owned by insiders.
Several large investors have recently made changes to their positions in the business. LPL Financial LLC lifted its position in shares of NeoGenomics by 2.4% in the second quarter. LPL Financial LLC now owns 19,250 shares of the medical research company’s stock worth $422,000 after buying an additional 455 shares during the last quarter. Municipal Employees Retirement System of Michigan lifted its position in shares of NeoGenomics by 1.6% in the third quarter. Municipal Employees Retirement System of Michigan now owns 30,870 shares of the medical research company’s stock worth $590,000 after buying an additional 490 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of NeoGenomics by 14.7% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,778 shares of the medical research company’s stock worth $110,000 after purchasing an additional 739 shares during the period. Yorktown Management & Research Co Inc increased its stake in shares of NeoGenomics by 4.6% in the second quarter. Yorktown Management & Research Co Inc now owns 18,300 shares of the medical research company’s stock worth $402,000 after purchasing an additional 800 shares during the period. Finally, Commonwealth Equity Services LLC increased its stake in shares of NeoGenomics by 3.8% in the second quarter. Commonwealth Equity Services LLC now owns 25,647 shares of the medical research company’s stock worth $562,000 after purchasing an additional 945 shares during the period. 85.00% of the stock is owned by institutional investors.
About NeoGenomics
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Featured Article: Exchange-Traded Funds (ETFs)
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source